Addex Therapeutics completes enrollment in part one of ADX71149 trial

Addex Therapeutics (ADXN) announced that enrollment into Part 1 of the Phase 2 clinical study of ADX71149 for the treatment of epilepsy has been completed. ADX71149 is a selective metabotropic glutamate type 2, or mGlu2, receptor positive allosteric modulator, or PAM. The trial is being conducted by Janssen Pharmaceuticals, part of Johnson & Johnson (JNJ). Data from Part 1 will now be evaluated by an independent interim review committee, or IRC, to ensure the study remains blinded. Based on the outcome of this review and recommendations from the IRC, Janssen will evaluate next steps for the program.